Acrux Limited (FRA:FJY)

Market Cap	3.63M -54.0%
Revenue (ttm)	664.32K -76.6%
Net Income	-3.32M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	500
Open	0.0065
Previous Close	0.0065
Day's Range	0.0065 - 0.0065
52-Week Range	0.0020 - 0.0205
Beta	n/a
RSI	93.11
Earnings Date	Feb 26, 2026

About Acrux

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazo...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 43
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: FJY

Financial Performance

In fiscal year 2025, Acrux's revenue was 1.19 million, a decrease of -76.63% compared to the previous year's 5.09 million. Losses were -5.95 million, 2.50% more than in 2024.

Financial numbers in AUD